Endocrinología, Diabetes y Nutrición NARRATIVE

Emerging Myostatin and Metabolic Hormone Pathway Modulators in Cardiometabolic Disease: Mechanisms, Evidence, and Therapeutic Potential

Myosteatosis in type 1 diabetes: immunometabolic mechanisms, biomarkers, and therapeutic targets

Myosteatosis, defined as pathological lipid accumulation within and between skeletal muscle fibers, is increasingly recognized as a determinant of impaired muscle quality, metabolic inflexibility, and adverse clinical outcomes. Although well described in ageing, obesity, and cancer, its relevance to type 1 diabetes (T1...

Sarcopenia and Skeletal Muscle Dysfunction in Liver Cirrhosis: Clinical Perspectives of Myostatin Inhibition

Liver cirrhosis is frequently complicated by sarcopenia, a progressive and systemic loss of skeletal muscle mass and function that contributes substantially to increased morbidity, mortality, and healthcare utilisation. The pathogenesis of sarcopenia in cirrhosis is multifactorial, involving hyperammonaemia, altered pr...

Targeting skeletal muscle wasting: Emerging therapeutics and translational challenges.

Skeletal muscle wasting is a multifactorial syndrome that contributes to weakness, reduced physical function, loss of independence, and poor clinical outcomes across aging, cancer, obesity, heart failure, disuse, and rare neuromuscular diseases. Although major advances have illuminated much of the molecular signaling f...

Growth Hormone Deficiency and Systemic Metabolic Remodeling: Insights from Metabolomics and Lipidomics

Growth hormone (GH) deficiency (GHD) is a systemic endocrine–metabolic disorder affecting growth, body composition, substrate handling, and cardiometabolic health. Clinical evaluation relies primarily on GH stimulation testing and circulating insulin-like growth factor 1 (IGF-1), but these measures incompletely reflect...

Adipocytokines as Pathogenic Mediators and Therapeutic Targets in Metabolic Syndrome-Related Cardiocerebrovascular Events

Current translational evidence is strongest for strategies targeting adiponectin/FGF21 signaling and IL-1/IL-6-related inflammatory pathways, while evidence for cerebrovascular outcomes remains limited, and adipokine-directed interventions remain promising but require rigorous clinical validation and disease-specific s...